Brigham and Women's Hospital Articles

Oncology Advances Spring 2015

Receive news, treatment options, research and clinical trials from Brigham and Women's Cancer Center

Issue link: http://brighamandwomens.uberflip.com/i/485884

Contents of this Issue

Navigation

Page 0 of 7

Page 2 New Immunotherapy Trials Introduce Novel Patient-specific Approaches to Brain Tumor Treatment Neuro-oncologists in the Center for Neuro-Oncology at Dana-Farber/Brigham and Women's Cancer Center are offering a portfolio of clinical trials in immunotherapy and new targeted therapies for patients with glioblastoma, glioma, and other brain tumors. Would you rather receive Advances via email? Register at brighamandwomens.org/MDNewsletters Page 7 Pinpointing Resistance Mutations in Anaplastic Thyroid Cancer A team of surgeons, medical oncologists, cancer researchers and geneticists at Dana-Farber/Brigham and Women's Cancer Center is working to improve outcomes for patients with anaplastic thyroid cancer. Page 6 National Clinical Trial Using TORS Aims to Decrease Extent of Treatment for Head and Neck Cancer Patients Specialists in head and neck cancer at Dana-Farber/Brigham and Women's Cancer Center are participating in a national clinical trial that risk stratifies patients with HPV-positive oropharyngeal squamous cell carcinoma following transoral robotic surgery (TORS) in an effort to reduce postoperative radiation and chemotherapy. Page 4 Immune Checkpoint Inhibitor Therapy Demonstrates High Response Rates At the American Society for Hematology (ASH) Annual Meeting in December 2014, Philippe Armand, MD, PhD, a medical oncologist in the Center for Hematologic Malignancies at Dana-Farber/Brigham and Women's Cancer Center, presented preliminary results from a Phase I trial of nivolumab, a monoclonal antibody directed against PD-1, in patients with relapsed or refractory Hodgkin Lymphoma. Change in Tumor Burden (%) Partial Response Stable Disease Complete Response Individual Patient Data (N = 23) ASCT Failure-Brentuximab Vedotin Failure ASCT Naïve-Brentuximab Vedotin Failure Brentuximab Vedotin Naïve 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 Spring 2015 ONCOLOGY Advances

Articles in this issue

Links on this page

view archives of Brigham and Women's Hospital Articles - Oncology Advances Spring 2015